Last reviewed 2026-05-20 · How we verify

ROLVEDON (EFLAPEGRASTIM-XNST)

SPECTRUM PHARMS · FDA-approved approved Under review Quality 10/100

ROLVEDON (generic name: EFLAPEGRASTIM-XNST) is a Leukocyte Growth Factor [EPC] drug developed by SPECTRUM PHARMS. It is currently FDA-approved for Febrile neutropenia caused by myelosuppressive anti-cancer drugs.

Eflapegrastim is a granulocyte colony-stimulating factor receptor agonist used to treat breast neoplasms. It works by activating the granulocyte colony-stimulating factor receptor, a protein involved in stimulating the production of white blood cells.

At a glance

Generic name	EFLAPEGRASTIM-XNST
Sponsor	SPECTRUM PHARMS
Drug class	Leukocyte Growth Factor [EPC]
Target	Granulocyte colony-stimulating factor receptor
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

Febrile neutropenia caused by myelosuppressive anti-cancer drugs

Common side effects

Fatigue
Nausea
Diarrhea
Bone pain
Headache
Pyrexia
Anemia
Rash
Myalgia
Arthralgia
Back pain
Decreased appetite

Serious adverse events

Splenic rupture
Acute respiratory distress syndrome
Serious allergic reactions
Sickle cell crisis
Glomerulonephritis
Leukocytosis
Capillary leak syndrome
Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)
Aortitis

Key clinical trials

Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ROLVEDON CI brief — competitive landscape report
ROLVEDON updates RSS · CI watch RSS
SPECTRUM PHARMS portfolio CI

Frequently asked questions about ROLVEDON

What is ROLVEDON?

ROLVEDON (EFLAPEGRASTIM-XNST) is a Leukocyte Growth Factor [EPC] drug developed by SPECTRUM PHARMS, indicated for Febrile neutropenia caused by myelosuppressive anti-cancer drugs.

What is ROLVEDON used for?

ROLVEDON is indicated for Febrile neutropenia caused by myelosuppressive anti-cancer drugs.

Who makes ROLVEDON?

ROLVEDON is developed and marketed by SPECTRUM PHARMS (see full SPECTRUM PHARMS pipeline at /company/spectrum-pharms).

What is the generic name of ROLVEDON?

EFLAPEGRASTIM-XNST is the generic (nonproprietary) name of ROLVEDON.

What drug class is ROLVEDON in?

ROLVEDON belongs to the Leukocyte Growth Factor [EPC] class. See all Leukocyte Growth Factor [EPC] drugs at /class/leukocyte-growth-factor-epc.

What development phase is ROLVEDON in?

ROLVEDON is FDA-approved (marketed).

What are the side effects of ROLVEDON?

Common side effects of ROLVEDON include Fatigue, Nausea, Diarrhea, Bone pain, Headache, Pyrexia. Serious adverse events: Splenic rupture, Acute respiratory distress syndrome, Serious allergic reactions, Sickle cell crisis.

What does ROLVEDON target?

ROLVEDON targets Granulocyte colony-stimulating factor receptor and is a Leukocyte Growth Factor [EPC].

Drug class: All Leukocyte Growth Factor [EPC] drugs
Target: All drugs targeting Granulocyte colony-stimulating factor receptor
Manufacturer: SPECTRUM PHARMS — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Febrile neutropenia caused by myelosuppressive anti-cancer drugs